LPAR1 and central nervous system cancer: In C6 glioma cells, an immortalized astrocyte cell line, inhibition of LPA1 activity by Ki16425 (an LPA1/3 antagonist) or AM966 (an LPA1 antagonist) can attenuate LPA-triggered ERK1/2 activation, which is reaffirmed by LPA1 knockdown with its specific siRNA [197].